Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice

Microbial Cell Factories

Volumn 14, Issue 1, 2015, Pages 1-

  Lei, Han ^a   Peng, Xiaojue ^b   Jiao, Huifeng ^b   Zhao, Daxian ^b   Ouyang, Jiexiu ^b  

^a SOUTHWEST JIAOTONG UNIVERSITY   (China)

^b NANCHANG UNIVERSITY   (China)

Author keywords

Cross protective immunity; Influenza A viruses; L. lactis pNZ8008 NP adjuvanted with CTB

Indexed keywords

ANTIVIRUS AGENT; CHOLERA TOXIN B SUBUNIT; HA1 PROTEIN; IMMUNOLOGICAL ADJUVANT; NUCLEOPROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; CHOLERA TOXIN; CORE PROTEIN; INFLUENZA VACCINE; NP PROTEIN, INFLUENZA A VIRUS; RNA BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA A VIRUS (A/CALIFORNIA/04/2009(H1N1)); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; LACTOCOCCUS LACTIS; MOLECULAR CLONING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; VACCINATION; VIROLOGY;

INFLUENZA A VIRUS; INFLUENZAVIRUS A; LACTOCOCCUS LACTIS; MUS; ORTHOMYXOVIRIDAE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; CHOLERA TOXIN; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LACTOCOCCUS LACTIS; MICE; MICE, INBRED BALB C; RNA-BINDING PROTEINS; VACCINATION; VIRAL CORE PROTEINS;

EID: 84939435743     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/s12934-015-0287-4     Document Type: Article

References (37)

1. Rappuoli R, Dormitzer PR (2012) Influenza: options to improve pandemic preparation. Science 336:1531-1533
2. World Health Organization (WHO) (2014) Influenza fact sheet. http://www.who.int/mediacentre/factsheets/fs211/en/
3. World Health Organization (WHO) (2014) Influenza at the human-animal interface. http://www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface:October14.pdf?ua=1
4. Schotsaert M, García-Sastre A (2014) Influenza Vaccines: a Moving Interdisciplinary Field. Viruses 6:3809-3826
5. Subbarao K, Joseph T (2007) Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 7:267-278
6. Epstein SL (2003) Control of influenza virus infection by immunity to conserved viral features. Expert Rev Anti-Infect Ther 1:627-638
7. Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, Brusic V et al (2007) Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS One 2:e1190
8. Uranowska K, Tyborowska J, Jurek A, Szewczyk B, Gromadzka B (2014) Hemagglutinin stalk domain from H5N1 strain as a potentially universal antigen. Acta Biochim Pol 61:541-550
9. Jang YH, Seong BL (2014) Options and obstacles for designing a universal influenza vaccine. Viruses 6:3159-3180
10. Moorthy NS, Poongavanam V, Pratheepa V (2014) Viral M2 ion channel protein: a promising target for anti-influenza drug discovery. Mini Rev Med Chem 14:819-830
11. Roose K, Fiers W, Saelens X (2009) Pandemic preparedness: toward a universal influenza vaccine. Drug News Perspect 22:80-92
12. Shu LL, Bean WJ, Webster RG (1993) Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. J Virol 67:2723-2729
13. Price GE, Lo CY, Misplon JA, Epstein SL (2014) Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model. J Virol 88:6019-6030
14. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV et al (2009) Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27:6512-6521
15. Jameson J, Cruz J, Terajima M, Ennis FA (1999) Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 162:7578-7583
16. McMichael AJ, Gotch FM, Noble GR, Beare PA (1983) Cytotoxic T-cell immunity to influenza. N Engl J Med 309:13-17
17. Ulmer JB, Fu TM, Deck RR, Friedman A, Guan L, DeWitt C et al (1998) Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 72:5648-5653
18. Hillaire MLB, Osterhaus ADME, Rimmelzwaan GF (2011) Induction of virus specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol 2011:939860
19. Lei H, Sheng Z, Ding Q, Chen J, Wei X, Lam DM et al (2011) Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B. Clin Vaccine Immunol 18:1046-1051
20. Elson CO, Ealding W (1985) Genetic control of the murine immune response to cholera toxin. J Immunol 135:930-932
21. Tamura S, Miyata K, Matsuo K, Asanuma H, Takahashi H, Nakajima K et al (1996) Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J Immunol 156:3892-3900
22. Kim SH, Kim JY, Choi Y, Nguyen HH, Song MK, Chang J (2013) Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection. PLoS One 8:e75460
23. Sanchez MV, Ebensen T, Schulze K, Cargnelutti D, Blazejewska P, Scodeller EA et al (2014) Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge. PLoS One 9:e104824
24. Lycke N (2012) Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 12:592-605
25. Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11:S45-S53
26. Wells JM, Mercenier A (2008) Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 6:349-362
27. Bahey-El-Din M, Gahan CG (2011) Lactococcus lactis-based vaccines: current status and future perspectives. Hum Vaccin 7:106-109
28. Lei H, Peng X, Shu H, Zhao D (2015) Intranasal immunization with live recombinant Lactococcus lactis combined with heat-labile toxin B subunit protects chickens from highly pathogenic avian influenza H5N1 virus. J Med Virol 87:39-44
29. Huang B, Wang W, Li R, Wang X, Jiang T, Qi X et al (2012) Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. Virol J 9:322
30. Sipo I, Knauf M, Fechner H, Poller W, Planz O, Kurth R et al (2011) Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV). Vaccine 29:1690-1699
31. Falkeborn T, Bråve A, Larsson M, Akerlind B, Schröder U, Hinkula J (2013) Endocine™, N3OAandN3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination. PLoS One 8:e70527
32. Liu H, Patil HP, de Vries-Idema J, Wilschut J, Huckriede A (2013) Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategies. PLoS One 8:e69649
33. Lamere MW, Lam HT, Moquin A, Haynes L, Lund FE, Randall TD et al (2011) Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 186:4331-4339
34. Lamere MW, Moquin A, Lee FE, Misra RS, Blair PJ, Haynes L et al (2011) Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol 85:5027-5035
35. Corthésy B, Benureau Y, Perrier C, Fourgeux C, Parez N, Greenberg H et al (2006) Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J Virol 80:10692-10699
36. Lei H, Xu Y, Chen J, Wei X, Lam DM (2010) Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules. Virology 407:319-324
37. Hong DK, Chang S, Botham CM, Giffon TD, Fairman J, Lewis DB (2010) Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity. J Virol 84:12691-12702